Tag: 100-200

On November 30, 2013, Abate, Carmen; Selivanova, Svetlana V.; Muller, Adrienne; Kramer, Stefanie D.; Schibli, Roger; Marottoli, Roberta; Perrone, Roberto; Berardi, Francesco; Niso, Mauro; Ametamey, Simon M. published an article.Related Products of 74904-29-3 The title of the article was Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors. And the article contained the following:

σ2 Receptors are promising biomarkers for cancer diagnosis given the relationship between the proliferative status of tumors and their d. With the aim of contributing to the research of σ2 receptor Positron Emission Tomog. (PET) probes, we developed 2-[3-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propyl]-3,4-dihydroisoquinolin-1(2H)-one (3), with optimal σ2 pharmacol. properties and appropriate lipophilicity. Hence, 3 served as the lead compound for the development of a series of dihydroisoquinolinones amenable to radiolabeling. Radiosynthesis for compound 26, which displayed the most appropriate σ2 profile, was developed and σ2 specific binding for the corresponding [18F]-26 was confirmed by in vitro autoradiog. on rat brain slices. Despite the excellent in vitro properties, [18F]-26 could not successfully image σ2 receptors in the rat brain in vivo, maybe because of its interaction with P-gp. Nevertheless, [18F]-26 may still be worthy of further investigation for the imaging of σ2 receptors in peripheral tumors devoid of P-gp overexpression. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Related Products of 74904-29-3

The Article related to brain, homo sapiens, human, positron emission tomography, tomography imaging agents, tumor imaging, σ1-non-opioid intracellular receptors role: bsu (biological study, unclassified), biol (biological study), σ2-non-opioid intracellular receptors role: bsu (biological study, unclassified), biol (biological study) and other aspects.Related Products of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On February 5, 2004, Taveras, Arthur G.; Aki, Cynthia J.; Chao, Jianping; Dwyer, Michael; Chao, Jianhua; Yu, Younong; Merritt, J. Robert; Biju, Purakkattle; Jakway, James; Lai, Gaifa; Wu, Minglang; Hecker, Evan A.; Lundell, Daniel; Fine, Jay S. published a patent.Product Details of 74904-29-3 The title of the patent was Preparation of 3,4-di(substituted amino)cyclobutene-1,2-diones as CXC-chemokine receptor ligands. And the patent contained the following:

Disclosed are novel compounds of the formula (I) or pharmaceutically acceptable salts or solvates thereof [A = Q, Q1; B = substituted Ph, (un)substituted 1H-pyrazol-3-yl, 1H-pyrazol-5-yl, 2- or 3-thienyl, 1H-pyrrol-3-yl, 1H-pyrrol-2-yl, isothiazol-3-yl, 1,2-dihydro-4-hydroxy-2-oxo-pyridin-3-yl, 4-hydroxypyrimidin-4-yl, or 4-hydroxypyridin-3-yl, 1,2-dihydro-4-hydroxy-2-oxo-pyridin-5-yl, 1,4-dihydro-1-hydroxy-4-oxopyridin-2-yl, 1H-benzotriazol-7-yl, 1H-benzimidazol-7-yl, 1H-indol-7-yl, or benzo[c]pyrazol-7-yl; R7, R8 = H, each (un)substituted alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, CO2H, CONH2, alkynyl, alkenyl, cycloalkenyl; R12 = H,each (un)substituted CO2H, aryl, heteroaryl, arylalkyl, cycloalkyl, alkyl, cycloalkylalkyl, or heteroarylalkyl group]. Also disclosed is the treatment of chemokine-mediated diseases, where the chemokine binds to CXCR2 and/or CXCR1 receptor, using compounds of the formula I. The diseases include chronic inflammation, acute inflammatory pain, chronic inflammatory pain, acute neuropathic pain, chronic neuropathic pain, psoriasis, atopic dermatitis, asthma, COPD, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, septic shock, endotoxic shock, gram neg. sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, Alzheimer’s disease, graft vs. host reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayed type hypersensitivity reaction, atherosclerosis, cerebral and cardiac ischemia, osteoarthritis, multiple sclerosis, restenosis, angiogenesis, osteoporosis, gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, Kaposi’s sarcoma associated virus, meningitis, cystic fibrosis, preterm labor, cough, pruritis, multiorgan dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, and subarachnoid hemorrhage. They also include post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alc. hepatitis, necrotizing enterocolitis, chronic sinusitis, angiogenic ocular disease, ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, cough, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD), granulocytic ehrlichiosis, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds, gout, alc. liver disease, lupus, burn therapy, periodontitis, transplant reperfusion injury and early transplantation rejection, acute inflammation, and rheumatoid arthritis as well as cancer. The compounds I had IC50 of <10 μM for inhibiting the binding of [125I]-IL-8 to human chemokine receptor CXCR1. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Product Details of 74904-29-3

The Article related to aminocyclobutenedione preparation cxc chemokine receptor ligand, inflammation treatment aminocyclobutenedione preparation, inflammatory pain treatment aminocyclobutenedione preparation, cancer treatment aminocyclobutenedione preparation, psoriasis treatment aminocyclobutenedione preparation, atopic dermatitis treatment aminocyclobutenedione preparation and other aspects.Product Details of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On March 13, 2014, St. Laurent, Denis R.; Serrano-Wu, Michael H.; Belema, Makonen; Ding, Min; Fang, Hua; Gao, Min; Goodrich, Jason T.; Krause, Rudolph G.; Lemm, Julie A.; Liu, Mengping; Lopez, Omar D.; Nguyen, Van N.; Nower, Peter T.; O’Boyle, Donald R. II; Pearce, Bradley C.; Romine, Jeffrey L.; Valera, Lourdes; Sun, Jin-Hua; Wang, Ying-Kai; Yang, Fukang; Yang, Xuejie; Meanwell, Nicholas A.; Snyder, Lawrence B. published an article.Related Products of 1367744-24-8 The title of the article was HCV NS5A Replication Complex Inhibitors. Part 4. Optimization for Genotype 1a Replicon Inhibitory Activity. And the article contained the following:

Sym. stilbene bis(acylprolinamides) such as I (R = PhCH2, 2-EtC6H4, Ph, 2-vinylphenyl, 1-naphthyl, 3-ethyl-2-pyridinyl, 4-ethyl-2-pyridinyl, 3-vinyl-2-pyridinyl, 3-phenyl-2-pyridinyl, 1-isoquinolyl, 3-isoquinolinyl, 2-quinolinyl, 4-isoquinolinyl, 4-quinazolinyl, 1-phthalazinyl, 3-chloro-1-isoquinolinyl, 4-chloro-1-isoquinolinyl, 5-chloro-1-isoquinolinyl, 6-chloro-1-isoquinolinyl, 7-chloro-1-isoquinolinyl, 3-fluoro-1-isoquinolinyl, 5-fluoro-1-isoquinolinyl, 3-methyl-1-isoquinolinyl, 5-methyl-1-isoquinolinyl, 3-methoxy-5-isoquinolinyl, 5-methoxy-1-isoquinolinyl, 3-chloro-1-naphthyl, 3-chloro-5-fluoro-1-isoquinolinyl, 3-chloro-5-methoxy-1-isoquinolinyl, 5-methoxy-2-quinolinyl, 7-methoxy-2-quinolinyl) derived from the library-synthesized lead I (R = PhCH2) were prepared as HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibitors; their selectivities for inhibition of HCV over general viral inhibition and their cytotoxicities to human Huh-7 cells were determined The structure-activity relationships for inhibition of HCV replication by sym. bis(prolinamide) HCV inhibitors were determined I (R = 1-isoquinolinyl) was a selective HCV NS5A inhibitor exhibiting submicromolar potency against both G-1a and G-1b replicons; further optimization identified I (R = 3-chloro-5-methoxy-1-isoquinolinyl) as a potent, dual G-1a/1b HCV NS5A inhibitor. The structure-activity relations derived from I were used in the discovery of the NS5A replication complex inhibitor daclatasvir II. The experimental process involved the reaction of 5-Methylisoquinoline-1-carbonitrile(cas: 1367744-24-8).Related Products of 1367744-24-8

The Article related to stilbene acylprolinamide preparation inhibition ns5a replication complex hepatitis c, structure bisacylprolinamide inhibition selectivity hepatitis c toxicity, hepatitis c genotype 1a replication inhibition stilbene acylprolinamide and other aspects.Related Products of 1367744-24-8

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 29, 2004, Taveras, Arthur G.; Aki, Cynthia J.; Bond, Richard W.; Chao, Jianping; Dwyer, Michael; Ferreira, Johan A.; Chao, Jianhua; Yu, Younong; Baldwin, John J.; Kaiser, Bernd; Li, Ge; Merritt, J. Robert; Biju, Purakkattle J.; Nelson, Kingsley H.; Rokosz, Laura L.; Jakway, James P.; Lai, Gaifa; Wu, Minglang; Hecker, Evan A.; Lundell, Daniel; Fine, Jay S. published a patent.Application of 74904-29-3 The title of the patent was Preparation of 3,4-diaminocyclobutene-1,2-diones as CXC-chemokine receptor ligands. And the patent contained the following:

Title compounds [I; A = (substituted) pyridylmethyl, thiazolylmethyl, benzofurylmethyl, isoxazolylmethyl, pyrazinylmethyl, triazolylmethyl, phenylalkyl, etc.; B = (substituted) Ph, benzotriazolyl, benzimidazolyl, imidazolyl, pyrazolyl, hydroxypyridinyl, thienyl, pyrrolyl, isothiazolyl, etc.], were prepared Thus, title compound (II) (preparation outlined) showed Ki = 0.8 nM in a CXCR2 SPA receptor binding assay. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Application of 74904-29-3

The Article related to aminocyclobutenedione preparation cxc chemokine receptor ligand, cyclobutenedione diamino preparation cxc chemokine receptor ligand, squaric acid amide preparation cancer pain inflammation contusion treatment and other aspects.Application of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On March 1, 2022, Zhou, Chao; Gan, Qi-Chao; Zhou, Tai-Ping; Lei, Tao; Ye, Chen; He, Xiao-Jun; Chen, Bin; Lu, Heng; Wan, Qian; Liao, Rong-Zhen; Tung, Chen-Ho; Wu, Li-Zhu published an article.Product Details of 1367744-24-8 The title of the article was Site-Selective N-1 and C-3 Heteroarylation of Indole with Heteroarylnitriles by Organocatalysis under Visible Light. And the article contained the following:

Site-selective N-1 and C-3 arylation of indole was sought after because of the prevalent application of arylindoles and the intricate reactivities associated with the multiple sites of the N-unsubstituted indole. Represented herein is the first regioselective heteroarylation of indole via a radical-radical cross-coupling by visible-light irradiation Steady and time-resolved spectroscopic and computational studies revealed that the hydrogen-bonding interaction of organic base and its conjugated acid, namely with indole and heteroarylnitrile, determined the reaction pathway, which underwent either proton-coupled electron-transfer or energy-transfer for the subsequent radical-radical cross-coupling, leading to the regioselective formation of C-3 and N-1 heteroarylation of indoles, resp. The parallel methodologies for regioisomeric N-1 and C-3 heteroaryl indoles with good functional group compatibility was applied to large-scale synthesis and late-stage derivatization of bioactive compounds under extremely mild reaction conditions. The experimental process involved the reaction of 5-Methylisoquinoline-1-carbonitrile(cas: 1367744-24-8).Product Details of 1367744-24-8

The Article related to indole isoquinolinecarbonitrile organocatalyst photochem regioselective heteroarylation, indolyl isoquinoline preparation, cross-coupling, heteroarylation, indoles, proton-coupled electron-transfer, radicals and other aspects.Product Details of 1367744-24-8

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 18, 1982, Kashdan, David S.; Schwartz, John A.; Rapoport, Henry published an article.Category: isoquinoline The title of the article was Synthesis of 1,2,3,4-tetrahydroisoquinolines. And the article contained the following:

Several aspects of 1,2,3,4-tetrahydroisoquinoline synthesis were examined An improved synthesis of 2-(m-methoxyphenyl)ethylamine (I) is reported. m-Anisaldehyde was treated with KCN and EtO2CCl to yield O-(ethoxycarbonyl)-3-methoxymandelonitrile. Hydrogenation gave I in 87% yield overall. Some observations were made regarding the reduction of 3,4-dihydroisoquinolines derived from the Bischler-Napieralski reaction. Amides II (R = R1 = MeO; R = H, R1 = OCH2Ph) were cyclized with POCl3 followed by reduction to the corresponding tetrahydroisoquinolines III, which were contaminated with 4% of IV (R = R1 = MeO) and 3% of IV (R = H, R1 = OCH2Ph), resp. Both IV (R = R1 = OMe) and IV (R = H, R1 = OCH2Ph) were independently synthesized by routes with general applicability to 8-alkoxy-1,2,3,4-tetrahydroisoquinolines. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Category: isoquinoline

The Article related to tetrahydroisoquinoline, hydroisoquinoline tetra, isoquinoline tetrahydro, phenethylbenzeneacetamide bischler napieralski cyclization, acetamide phenethylbenzene cyclization and other aspects.Category: isoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 6, 2021, Yu, Hongtao; Hu, Qi; Huang, Jing; Wang, Tingliang; Hou, Ningke; Zhang, Lijing; Zhang, Wenyi; Tan, Qiaozhu published a patent.Synthetic Route of 1378839-26-9 The title of the patent was Preparation of heterocyclic derivatives as 3C like protease inhibitors. And the patent contained the following:

The invention relates to the preparation of heterocyclic derivatives with general formula I as 3C like protease inhibitors, where Ar = Ph or 6-membered heteroaryl; ring A = 9 or 10-membered heteroaryl, wherein: V1 , V2, V3, and V4 = not present, CH or N; and at most one of V1, V2, V3, and V4 may not exist; when one of W1, W2, W3, and W4 does not exist, then V1, V2, V3, and None of V4 can be absent; W1, W2, W3, and W4 = not present, CH or N; at most one of W1, W2, W3, and W4 can be absent; at least one of W1, W2, W3, and W4 must be N; X = absent, NRa or NRa(CRbRc)a; Y = absent, C3-C12 carbocyclyl, 3-12 membered heterocyclic group, or 5-10 membered heteroaryl; Z = absent, NRd, (CReRf)bNRd or C(=O)NRd(CRgRh)c; Ra and Rd = hydrogen or C1-C4 alkyl; Rb, Rc, Re and Rf = hydrogen or substituted C1-C4 alkyl; Rg and Rh = hydrogen or substituted C1-C4 alkyl; Ri and Rj = hydrogen or C1-C4 alkyl; a, b and c = 1, 2, 3 or 4; R1, R2. And R3 = halogen, cyano, C1-C6 alkane Group, C2-C6 alkenyl, C1-C6 alkoxy, C(=O)(C1-C6 alkyl), C(=O)NRpRq, NRpRq, NRpC(=O)Rs, NRpC(=O)ORs , NRpC(=O)NRqRr, NRpS(=O)wRs, NO2, NO2+, NH(=O)OH, ORs, OC(=O)Rs, OC(=O)ORs, OC(=O)NRpRq, S(=O)wRs, S(=O)wNRpRq, SO3, C3-C12 carbocyclic group, 3-12 membered heterocyclic group, Ph, 5-10 membered heteroaryl; Rp, Rq and Rr = hydrogen, C1-C4 alkyl or C3-C6 cycloalkyl; Rs = hydrogen, C1-C4 alkyl or C3-C6 cycloalkyl; m = 0 For example, 5-bromo-2-((1-(5-hydroxyisoquinoline-4-carbonyl)piperidin-3-yl)amino)-N-methyl-3-nitrobenzamide was prepared by a multi-step reaction. The title compounds have good inhibitory effect on 3C like protease and can be used to treat SARS-COV-2 infection. The experimental process involved the reaction of 7-Hydroxyisoquinoline-4-carboxylic acid(cas: 1378839-26-9).Synthetic Route of 1378839-26-9

The Article related to amidation coupling hydrolysis preparation piperazine isoquinoline treatment human coronavirus, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 1378839-26-9

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Burkart, V.; Blaeser, K.; Kolb, H. published their research in Hormone and Metabolic Research on December 31 ,1999. The article was titled 《Potent β-cell protection in vitro by an isoquinolinone-derived PARP inhibitor》.Recommanded Product: 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one The article contains the following contents:

Activation of the nuclear enzyme poly(ADP-ribose)polymerase (PARP) is a critical step in β-cell death in response to exposure with free radicals or other DNA damaging agents. Nicotinamide, a B vitamin, exerts its β-cell protective action primarily via its ability to block excessive PARP activity. We show here that the isoquinolinone derivative PD128763, a specific PARP inhibitor, provides protection from cell death in islet cells exposed in vitro to nitric oxide or oxygen radical generating compounds or to the β-cell toxin streptozotocin, at concentrations 100 times less than required for nicotinamide. Furthermore, while the protective action of nicotinamide is rapidly lost after washing of islet cells, the effects of PD128763 are more long lasting. Both compounds had little capacity to rescue damaged islet cells from subsequent lysis. We conclude that the isoquinolinone derivative PD128763 is superior to nicotinamide in enhancing the resistance of β-cells towards inflammatory attacks. After reading the article, we found that the author used 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5Recommanded Product: 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one)

5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5) belongs to isoquinoline. Isoquinoline is a structural isomer of quinoline, and quinoline derivatives are fused ring compounds of pyridine and benzene rings, which have antiseptic, antipyretic and anti-cyclic properties, and can be used as antimalarial drugs and for the preparation of other antimalarial medicine. Recommanded Product: 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Arundel-Suto, Carla M.; Scavone, Sylvia V.; Turner, William R.; Suto, Mark J.; Sebolt-Leopold, Judith S. published an article in Radiation Research. The title of the article was 《Effects of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on x-ray-induced cellular recovery processes in Chinese hamster V79 cells》.Reference of 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one The author mentioned the following in the article:

The modifying effects of PD 128763 (3,4-dihydro-5-methyl-1(2H)-isoquinolinone) (I), a potent inhibitor of poly(ADP-ribose)polymerase, on radiation-induced cell killing were examined in Chinese hamster V79 cells. I has an IC50 value against the purified enzyme 50-fold lower than 3-aminobenzamide (3-AB), a widely used specific inhibitor of the enzyme. Exposure of exponentially growing cells to a noncytotoxic concentration (0.5 mM) of I for 2 h immediately following x-irradiation increased their radiation sensitivity, modifying both the shoulder and the slope of the survival curve. When recovery from sublethal damage and potentially lethal damage was examined in exponential and plateau-phase cells, resp., postirradiation incubation with 0.5 mM I not only to inhibited both these processes fully, but also enhanced further the level of radiation-induced cell killing. This is in contrast to the slight effect seen with the less potent inhibitor, 3-AB. The mechanism of radiosensitization by I is related to the potent inhibition of poly(ADP-ribose) polymerase by this compound After reading the article, we found that the author used 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5Reference of 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one)

5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5) belongs to isoquinoline.Reference of 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one Isoquinoline is a structural isomer of quinoline, and quinoline derivatives are fused ring compounds of pyridine and benzene rings, which have antiseptic, antipyretic and anti-cyclic properties, and can be used as antimalarial drugs and for the preparation of other antimalarial medicine.

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Yau, Lorraine; Litchie, Brenda; Zahradka, Peter published their research in Experimental Cell Research on December 10 ,2004. The article was titled 《MIBG, an inhibitor of arginine-dependent mono(ADP-ribosyl)ation, prevents differentiation of L6 skeletal myoblasts by inhibiting expression of myogenin and p21cip1》.Formula: C10H11NO The article contains the following contents:

The development of skeletal muscle is controlled by a highly synchronized series of cellular events, and various signals from both inside and outside the cell play a role in the switch from multipotential mesodermal stem cells to muscle fibers. Meta-iodobenzylguanidine (MIBG), an inhibitor of mono(ADP-ribosyl)ation, has been shown to prevent terminal differentiation of skeletal myoblasts; however, its mechanism of action has not been established. We recently reported that MIBG is capable of preventing phenotypic modulation of smooth muscle cells by interfering with specific trans-acting factors [L. Yau, B. Litchie, S. Thomas, B. Storie, N. Yurkova, P. Zahradka, Endogenous mono-ADP-ribosylation mediates smooth muscle cell proliferation and migration via protein kinase N-dependent induction of c-fos expression. Eur. J. Biochem. 270 (2003) 101-110.]. We therefore examined the effect of MIBG on select myogenic regulatory factors known to control terminal differentiation. It was confirmed that MIBG, but not inhibitors of poly-ADP-ribose polymerase (3-aminobenzamide, PD128763), inhibits fusion of L6 skeletal myoblasts in a concentration-dependent manner. Moreover, inhibition by MIBG correlated with a failure to induce expression of myogenin and p21cip1, while levels of MyoD and MEF2 were unaffected. Time-of-addition studies revealed that MIBG also affected a late event possibly linked to cell fusion. Finally, arginine-dependent mono(ADP-ribosyl)transferase activity increased over the first 24 h of the differentiation period. These data support a role for arginine-dependent mono(ADP-ribosyl)transferase as an essential pos. regulator of differentiation in skeletal muscle cells that operates by modulating the expression of specific myogenic factors. The results came from multiple reactions, including the reaction of 5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5Formula: C10H11NO)

5-Methyl-3,4-dihydroisoquinolin-1(2H)-one(cas: 129075-56-5) belongs to isoquinoline. Isoquinoline is a structural isomer of quinoline, and quinoline derivatives are fused ring compounds of pyridine and benzene rings, which have antiseptic, antipyretic and anti-cyclic properties, and can be used as antimalarial drugs and for the preparation of other antimalarial medicine. Formula: C10H11NO

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem